BZAD-01

• UNSPSC Description:

  BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation[1].

• Target Antigen:

  iGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/bzad-01.html

• Purity:

  99.81

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|Methanol : 250 mg/mL (ultrasonic)

• Smiles:

  N=C(NCC1=C(C(F)(F)F)C=CC=C1)C2=CC=C(C=C2)OC(F)(F)F

• Molecular Weight:

  362.27

• References & Citations:

  [1]Truong L, et, al. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res Bull. 2009 Feb 16;78(2-3):91-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  305339-41-7